Chordia Therapeutics Inc. (JP:190A) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chordia Therapeutics Inc. has announced that the World Health Organization has given an International Nonproprietary Name, rogocekib, to their CLK inhibitor CTX-712, which is currently undergoing Phase 1/2 clinical trials in the U.S. This development marks a significant step towards the commercialization of CTX-712, a promising cancer therapy.
For further insights into JP:190A stock, check out TipRanks’ Stock Analysis page.